Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1

The existing repertoire of HIV-1 patient derived broadly neutralising antibodies (bNAbs) that target the HIV-1 envelope glycoprotein (Env) present numerous and exciting opportunities for immune-based therapeutic and preventative strategies against HIV-1. Combination antibody therapy is required to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Moshoette, Tumelo, Ali, Stuart Alvaro, Papathanasopoulos, Maria Antonia, Killick, Mark Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842167/
https://www.ncbi.nlm.nih.gov/pubmed/31703699
http://dx.doi.org/10.1186/s12977-019-0493-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842167/
https://www.ncbi.nlm.nih.gov/pubmed/31703699
http://dx.doi.org/10.1186/s12977-019-0493-y

Ejemplares similares